- Molecular NameLepirudin
- SynonymHirudin variant-1
- Weight6963.52
- Drugbank_IDDB00001
- ACS_NO138068-37-8
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)N/A
- pka4.04
- LogD (pH=7, predicted)N/A
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)N/A
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond DonorsN/A
- No.of HBond AcceptorsN/A
- No.of Rotatable BondsN/A
- TPSAN/A
- StatusFDA approved
- AdministrationSQ or IV
- PharmacologyAn anticoagulant which functions as a direct thrombin inhibitor.
- Absorption_valueN/A
- Absorption (description)Lepirudin is rapidly distributed and essentially confined to extracellular fluids.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding10.0
- Volume of distribution (VD)12.2 L (young and healthy); 18.7 L (healthy elderly); 18.0 L (renally impaired); 32.1 L (patients with heparin induced thrombocytopenia).
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolism and excretion mainly take place in the kidneys with little in the liver.
- Half life1.3 h.
- ExcretionApprox. 48% of an administered dose is detected in urine with 35% as the unchanged drug. Metabolic pathways are not fully established. It is thought that catabolic hydrolysis of the parent drug causes a release of amino acids. Plasma concentrations increase proportionally with the dose and there is no evidence of accumulation.
- Urinary ExcretionN/A
- CleranceMean, 164 mL/min (young and healthy); 139 mL/min (elderly and healthy); 61 mL/min (patients with renal impairment); 114 mL/min (patients with heparin induced thrombocytopenia). In female patients, systemic clearance is approx. 25% lower compared to male patients.
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A